

# Glucocorticoid replacement therapy and fibrinolysis.

<b>Submission date</b> 30/09/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 30/09/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 31/08/2010	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Steve Peacey

**Contact details**  
Diabetes & Endocrinology  
Bradford Royal Infirmary  
Duckworth Lane  
Bradford  
United Kingdom  
BD9 6RJ  
+44 (0)1274 382019  
srpeacey@talk21.com

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N0050153132

# Study information

## Scientific Title

### Study objectives

To determine whether the dose of adrenal steroid replacement therapy in patients with pituitary disease, influences the fibrinolytic system (clot breakdown system) and determine whether patients who receive higher adrenal steroid replacement dose are at greater risk of cardiovascular disease.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

### Study type(s)

Treatment

## Participant information sheet

### Health condition(s) or problem(s) studied

Nutritional, Metabolic, Endocrine: Hypopituitarism

### Interventions

The study will be of randomised, open-label, crossover design, comparing the effects of traditional glucocorticoid replacement regimens versus modern regimens on fibrinolytic parameters in patients with hypopituitarism.

Patients will have a two week period of treatment with either their current 'optimised' treatment regimen or with a higher dose (approx 30 - 50%) traditional type regimen. At the end of each two week period they will be admitted to a day case ward for hourly blood sampling over a 10 hour period. Blood will be taken for cortisol levels (adrenal steroid) in a standard fashion (a cortisol day profile) and for fibrinolytic parameters (i.e twice in total).

### Intervention Type

Other

**Phase**

Not Specified

**Primary outcome measure**

Fibrinolytic parameter measurements.

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

19/11/2004

**Completion date**

01/04/2007

## Eligibility

**Key inclusion criteria**

All patients over 18 years with documented adult hypopituitarism with proven ACTH deficiency, currently under follow up in the Bradford Teaching Hospitals NHS Trust, who have provided informed consent will be potentially eligible to participate in the study. Patients will be recruited from either direct contact in OPD or via direct phone contact with an endocrine specialist nurse.

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Not Specified

**Target number of participants**

15 patients and 10 controls will be recruited for the study.

**Key exclusion criteria**

1. Subjects requiring systematic steroid therapy
2. Subjects taking HRT or oral contraceptive
3. Subjects who are currently pregnant or who had recent pregnancy or abortion
4. Subjects with known malignancy
5. Subjects with known coagulopathy
6. Subjects who are currently taking or have recently taken anticoagulant therapy

**Date of first enrolment**

19/11/2004

**Date of final enrolment**

01/04/2007

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre****Diabetes & Endocrinology**

Bradford

United Kingdom

BD9 6RJ

## **Sponsor information**

**Organisation**

Department of Health

**Sponsor details**

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

+44 (0)20 7307 2622

dhmail@doh.gsi.org.uk

**Sponsor type**

Government

**Website**

<http://www.dh.gov.uk/Home/fs/en>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

Bradford Teaching Hospitals NHS Foundation Trust (UK) Own account but no NHS R&D Support Funding

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Abstract results</a>	results presented at Society for Endocrinology BES	06/11/2010		No	No